Related references
Note: Only part of the references are listed.Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Jasmine Davda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du et al.
CELL RESEARCH (2018)
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
Paul G. Baverel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Fei Tang et al.
CELL AND BIOSCIENCE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefania Paula Julia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Kathleen E. Fenerty et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in PatientsWith Metastatic Solid Tumors
Shruti Agrawal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody
Caroline Jochems et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Renee N. Donahue et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab
Swati Khanna et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Alena Gros et al.
NATURE MEDICINE (2016)
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark J. Selby et al.
PLOS ONE (2016)
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
Rika Fujii et al.
ONCOTARGET (2016)
Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010
Marianne van Vugt et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Human IgG4: a structural perspective
Anna M. Davies et al.
IMMUNOLOGICAL REVIEWS (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A High-Yielding CHO Transient System: Coexpression of Genes Encoding EBNA-1 and GS Enhances Transient Protein Expression
Olalekan Daramola et al.
BIOTECHNOLOGY PROGRESS (2014)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
Stefania Laurent et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Rong Rong Huang et al.
CLINICAL CANCER RESEARCH (2011)
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
Sameena Khan et al.
CLINICAL IMMUNOLOGY (2011)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Structural characterization of a human Fc fragment engineered for lack of effector functions
Vaheh Oganesyan et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2008)
Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
Lucie Baudino et al.
JOURNAL OF IMMUNOLOGY (2008)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
